Audit: QRS - PEMF Therapy for Health & Longevity
Audit conducted on 30/08/2026 02:02 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 84 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol, time-to-effect, benefit, risk, gate, marker and qualitative content traces to ER lines 155–189, 257–302, 321–343, 365–369, 416, 446–463, 489–493. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “No manufacturer-independent trial validates this schedule” carried verbatim from ER line 369; speculative tiers retained as speculative. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications retain absolute framing (“Pregnancy at any stage”); cautions retain “caution” / “monitor” / “no known interaction” exactly as ER lines 323–335. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gates draw only from ER Key Interactions & Contraindications; risks only from ER Potential Risks & Side Effects; no modifying-factor content migrated. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries none of these; ER brand names (Orthofix, DJO, Bemer, HigherDOSE) are correctly dropped rather than reused. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No named source, author, institution or manufacturer appears anywhere in the sheet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, sceptical register of the ER conclusion is preserved (“Outside that band the record thins quickly”). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Names where the signal holds and where it does not, with actionable tracking markers. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Protocols are described as “the pattern used in the … trials”, not prescribed. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Monitoring cadence and qualitative items are stated as observations, not instructions. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No recommending verbs anywhere in the populated spans. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun occurs in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms appear only where the ER table requires them (CTX, P1NP, DXA T-score, hs-CRP). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every ER bullet reduced to a phrase; benefit and risk tiers collapsed to semicolon-separated key facts. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed; no direct address in any span. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing assumes a reader weighing device purchase, cost, and a defined trial period. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Multi-hour daily wear and 4–8 week clinic schedules are presented without hedging on inconvenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Seven-marker laboratory panel and six qualitative trackers assume a committed reader. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Manufacturer financial interest and lack of independent validation are surfaced in the protocol cells, matching ER lines 367–369. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the title uses “Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terminology throughout; the plain-language wording in At-A-Glance is mandated by item 7.4 and mirrors the ER conclusion. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All present byte-identical to the template (lines 446, 492, 537, 572, 590, 630, 654, 658–660, 769). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variables present; the repeatable marker_#* and qualitative_item# rows are expanded to 7 and 6 instances. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Structural diff against the template shows changes confined to checklist-addressed variable regions; CSS, footer, and website=”” spans untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No QRS-mapped ER section is empty. The only empty-state case is the ER High risk tier, which item 13.5 explicitly requires to be hidden rather than filled with empty-state phrasing. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | All seven Key Interaction labels and all three protocol labels reproduce the ER bold labels verbatim (ER lines 323–335, 365–369). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names verbatim from the ER biomarker table; time-to-effect labels derive from ER wording (“pain outcomes”, “knee-strength effect”) as required by item 11.4. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Codepoint scan returns no emoji; the ER’s ⚠️ Conflicted markers are correctly stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed relative to the ER; the A4 print rules are intact and no section is extended with ER prose. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after the doctype at line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13; the title text at line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no duplicate of any metadata value appears in the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: pemf_therapy_2026-0830-0015_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0830-0148. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no context-window or other qualifier appended. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s actual name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Confirmed across all nine keys, including the unquoted numeric git_issue: 5617. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “PEMF Therapy for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “PEMF Therapy for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/30/2026”, correctly derived from 2026-0830-0148. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header carries only the title and the template subline; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER lines 489–491: mechanism, the narrow band where evidence holds, and the real cost. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to ER lines 489 and 491. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “arthritis”, “thinning bones”, “dummy devices” replace osteoarthritis, osteoporosis and sham; no acronym appears. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No author, year, or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No SMD, confidence interval, or numeric result appears. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from the “Populations who should avoid PEMF Therapy” list at ER lines 337–343. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER avoidance populations are present, and the ER’s absolute cardiac-device contraindication (line 321) is folded into item one. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Five <li> elements at lines 575–585. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | ER trailing rationale stripped: “given complete absence of trial data” and “per manufacturer labelling” removed; no dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “using unipolar leads”, “unless cleared by the implanting cardiologist”, “(head-targeted devices)”, and “in the treatment field” all preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names five such populations, and the section is correctly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from ER lines 321–335. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Seven of the ER’s eight interaction bullets carried; the implanted cardiac device bullet (ER line 321) correctly excluded because it appears in Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Seven <li> elements at lines 593–620. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item reduced to label plus verdict; ER mechanism and mitigation sentences dropped; no dash-trailing clauses. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Drug lists (warfarin, apixaban, clopidogrel), (prednisone, methotrexate), (ibuprofen, naproxen, acetaminophen) and the additive supplement and intervention lists are all preserved. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names eight such entries, and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Sourced from ER Therapeutic Protocol lines 365–369. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The ER’s three named regimens — standard clinical, home whole-body mat, and orthopedic bone stimulator — are the three actionable schedules in the section. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides three distinct regimens, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated; labels verbatim from the ER bold labels, values and subs condensed from the same bullets. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Pain (ER line 416), balance and mobility (ER line 175), and knee extensor strength (ER lines 189 and 416). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Pain and balance are High-tier benefits and lead; knee extensor strength is Medium-tier and comes last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects, so no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated; values “3–6 weeks”, “Immediately after intervention”, and “6 months” all traceable to ER lines 175, 189, 416. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All fourteen entries map one-to-one to the ER benefit headings at lines 151–237. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at lines 539–565, matching the ER’s five High, three Medium, four Low, and two Speculative benefits. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the bare ER heading; all Magnitude paragraphs, SMDs, and confidence intervals are dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses occur in any benefits span. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers carry ER content, so no sub-section is empty. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All six entries map to the ER risk headings at lines 261–301. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 632–648. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the bare ER heading; the Magnitude data (microtesla figures, 52 of 58 participants, SMD −0.38) is dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses occur in any risks span. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER states “No risk reaches High” (line 263); line 632 correctly renders <span data-qrs-var="risks_high" style="display: none"></span> with no empty-state text. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Sourced from the ER Monitoring Protocol & Defining Success table at lines 446–454. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All seven ER biomarkers present with names, targets, and rationale reproduced verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 758–763 condense ER lines 442–444: baseline, 4 and 8 weeks, 3 months, 12 months, and the 8–12 week reassessment. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Sourced from the ER’s qualitative marker list at lines 458–463. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers present and verbatim at lines 772–800. |
Issues 30/08/2026 02:02
Pass rate 100.00%. No issues found.
Issues 30/08/2026 01:55
- 7.2 — At-a-glance exceeds word limit: [at_a_glance] (QRS lines 434-438) runs to 61 words, one over the 60-word ceiling.
- 11.4 — Time-to-effect sub restates value: [time_1_sub] “Shift within 3–6 weeks of regular sessions” (QRS line 504) merely repeats [time_1_value] “3–6 weeks” (line 501) instead of adding ER-derived context, unlike the other two time cells.
Fixes 30/08/2026 01:55
- 7.2 — At-a-glance trimmed under 60 words: Condensed “in the days after surgery” to “after surgery” in [at_a_glance], bringing the summary from 61 to 58 words.
- 11.4 — Time-to-effect sub no longer restates value: Replaced [time_1_sub] “Shift within 3–6 weeks of regular sessions” with “Seen in the trial literature with regular sessions”, so the cell adds ER-derived context instead of repeating [time_1_value].